CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 45 enrolled
Drug / intervention
Sapropterin Dihydrochloride +1 moredrug
Likely dose
Sapropterin dihydrochloride (Phenoptin) 20 mg/kg/day orally once dailyAI-extracted
Key inclusion· 6
  • Clinical diagnosis of PKU with hyperphenylalaninemia documented by blood phenylalanine ≥360 μmol/L (6 mg/dL)
  • Under dietary control with phenylalanine-restricted diet and estimated daily phenylalanine tolerance ≤1000 mg/day
  • At least 6 months of blood phenylalanine control (mean level ≤480 μmol/L) prior to enrollment
  • Aged 4 to 12 years inclusive at screening
Key exclusion· 6
  • Any condition that renders subject at high risk for treatment non-compliance or inability to complete the study
  • Prior history of organ transplantation
  • Perceived to be unreliable or unavailable for study participation
  • Use of investigational agent within 30 days prior to screening or requirement for investigational agent/vaccine before study completion

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00272792
NCT00272792Phase 3Completed

A Phase 3, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of Phenoptin to Increase Phenylalanine Tolerance in Phenylketonuric Children on a Phenylalanine-restricted Diet

BioMarin Pharmaceutical·interventional·Posted Jan 9, 2006·Updated Aug 13, 2015

In Brief

A Phase 3 clinical trial evaluating Sapropterin Dihydrochloride and Placebo for Phenylketonurias. Completed, enrolled 45 participants across 9 sites.

Detailed Summary

The primary objective of this trial is to evaluate the ability of Phenoptin to increase phenylalanine (phe) tolerance in children with phenylketonuria who are following a phe-restricted diet.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--

Timeline

Phase 3CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJan 9, 2006
Enrollment StartFeb 1, 2006
Study CompletionNov 1, 2006
TodayJul 2, 2026
Posted 20.5 years ago

Interventions

Sapropterin Dihydrochloridedrug

Phenoptin, provided in tablets containing 100 mg of sapropterin dihydrochloride each, was administered orally once daily in the morning as the number of tablets equivalent to a 20mg/kg/day dose dissolved in 4-8 oz (120-240 mL) of water or apple juice for 6 weeks. A follow-up call or visit was made 4 weeks later during this double-blind, placebo-controlled study.

Placebodrug

Placebo, provided as tablets similar to Phenoptin tablets, was administered orally once daily in the morning as the number of tablets equivalent to a 20mg/kg/day dose dissolved in 4 8 oz (120-240 mL) of water or apple juice. for 6 weeks. A follow-up call or visit was made 4 weeks later during this double-blind, placebo-controlled study.